Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 1/20 | 0.45 |
| ▸ | BRAF | P15056 | 9/20 | 0.44 |
| ▸ | KDR | P35968 | 6/20 | 0.44 |
| ▸ | GRM5 | P41594 | 2/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | RAF1 | P04049 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | CDK8 | P49336 | 1/20 | 0.41 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3994618 | 0.91 | RAF1 (0.54) | BRAFKDRGRM5RAF1TRPV1 | |
| SCHEMBL3985934 | 0.89 | KDR (0.58) | BRAFKDR | |
| SCHEMBL3984127 | 0.87 | GPR52 (0.52) | NR3C2BRAFKDRGRM5MAPK14 | |
| SCHEMBL14273368 | 0.86 | TRPV1 (0.45) | NR3C2BRAFRAF1TRPV1CDK8 | |
| SCHEMBL5123479 | 0.85 | RAF1 (0.57) | BRAFKDRMAPK14RAF1TRPV1 | |
| SCHEMBL3989075 | 0.85 | GPR52 (0.50) | NR3C2BRAFKDRMAPK14GPR52 | |
| SCHEMBL3991944 | 0.84 | GRM5 (0.58) | GRM5TRPV1 | |
| SCHEMBL5119964 | 0.83 | NPC1 (0.55) | NR3C2BRAFGRM5 | |
| SCHEMBL4293095 | 0.83 | GRM5 (0.49) | NR3C2BRAFGRM5TRPV1CA1 | |
| SCHEMBL4115551 | 0.82 | BRAF (0.50) | NR3C2BRAFKDRGRM5MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2061761-A1 | PHENETHYLAMIDE DERIVATIVES WITH KINASE INHIBITORY ACTIVITY | Millennium Pharmaceuticals, Inc. (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20080064729-A1 | Phenethylamide derivatives with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-03-13 | — | — | US | disclosed |
| US-20080064729-A1 | Phenethylamide derivatives with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-03-13 | — | — | US | disclosed |
| WO-2008030448-A1 | PHENETHYLAMIDE DERIVATIVES WITH KINASE INHIBITORY ACTIVITY | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064729-A1 | Phenethylamide derivatives with kinase inhibitory activity | MAP4K5, MAP3K5, MAP4K2 | NR3C2 3563/4885BRAF 242/4885KDR 1073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.